VOYA Investment Management
MLTX icon

VOYA Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

VOYA Investment Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-246,114
Closed -$11.6M – 2572
2025
Q2 		$11.6M Sell
246,114
-146,810
-37% -$5.98M 0.01% 690
2025
Q1 		$15.4M Sell
392,924
-55,936
-12% -$2.41M 0.02% 607
2024
Q4 		$24.3M Buy
448,860
+39,657
+10% +$2.02M 0.03% 485
2024
Q3 		$20.6M Buy
409,203
+350,958
+603% +$16.4M 0.02% 540
2024
Q2 		$2.56M Sell
58,245
-5,490
-9% -$233K ﹤0.01% 1241
2024
Q1 		$3.2M Sell
63,735
-9,325
-13% -$506K ﹤0.01% 1163
2023
Q4 		$4.41M Buy
73,060
+37,970
+108% +$1.96M ﹤0.01% 1048
2023
Q3 		$2M Hold
35,090
– – ﹤0.01% 1333
2023
Q2 		$1.79M Buy
+35,090
New +$944K ﹤0.01% 1393

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VOYA Investment Management's MLTX Position: Q3 2025 in Review

VOYA Investment Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 246,114 shares — an estimated $11.6M sold.

VOYA Investment Management first reported a position in MLTX in Q2 2023 and held it in 9 quarters. The position peaked at $24.3M in Q4 2024. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • VOYA Investment Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • VOYA Investment Management sold 246,114 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $11.6M.
  • VOYA Investment Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 9 quarters.
  • VOYA Investment Management's MoonLake Immunotherapeutics position peaked at $24.3M in Q4 2024.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on VOYA Investment Management's 13F filing for Q3 2025, filed 9 Oct 2025.